In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA eases Tekmira Ebola drug hold; CDC chief wary

This article was originally published in Scrip

Executive Summary

Within hours after the head of a House subcommittee questioned why the FDA was keeping a clinical hold on Tekmira Pharmaceuticals' experimental Ebola drug in the midst of unprecedented outbreak of the disease in Western Africa – now declared a public health emergency of international concern by the World Health Organization – the US drug agency gave the company the go-ahead to use the investigational medicine in patients infected with the deadly virus.



Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts